Navigation Links
Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
Date:9/2/2008

eks, 300 mg every two weeks or 405 mg every four weeks), to a low reference dose of olanzapine LAI (45 mg every four weeks), or remained on oral olanzapine at their previously stabilized dose. No supplementation with oral antipsychotics was permitted during the study.

An assessment of clinical stability was based on change in oral olanzapine dose as well as standard measures including Clinical Global Impressions- Improvement of Illness (CGI-I) and Brief Psychiatric Rating Scale (BPRS) scales. Symptom severity was assessed using the Positive and Negative Syndrome (PANSS), PANSS-derived BPRS, and the Clinical Global Impressions-Severity of Illness (CGI-S) and CGI-I scales.

Therapeutic doses of olanzapine LAI were shown to provide positive maintenance of treatment for up to six months. Mean baseline-to-endpoint changes in PANSS total scores for patients treated with therapeutic olanzapine LAI doses (150 mg every 2 weeks, 300 mg every 2 weeks and 405 mg every 4 weeks) differed significantly from those treated with the reference dose (respectively, 2.7, -2.2, -0.1, vs. 7.3; all p<.001). Significant separation in PANSS total scores was seen between the therapeutic doses (150 mg/two weeks, 300 mg/two weeks, 405 mg/four weeks) versus the reference dose (45 mg/four weeks) starting at 11, three, and two weeks, respectively, and maintained throughout the study (p<.05).

Similar differences between therapeutic and reference olanzapine LAI doses were observed for the BPRS total, CGI-I, and CGI-S scores. Mean baseline-to- endpoint change in PANSS total score for the oral olanzapine group (-1.7) did not differ significantly from that of the highest olanzapine LAI dose group (-2.2, 300 mg/2 weeks; p=0.606) but was greater than the other olanzapine LAI doses (p<0.01).

The safety profile for olanzapine LAI was consistent with that of oral olanzapine except for injection-related events. The rate of discontinuation was low over six months of treatment. Incide
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
3. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
4. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
5. New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
6. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
7. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
8. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
9. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
10. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Biopharmaceutical Industry Leads Manufacturing Sector in R&D ... top as the country,s manufacturing leader in innovation and ... According to the  analysis , the industry had the ... decade, accounting for 27 percent of average annual R&D ... Video on Medicare Part D - Medicare Part ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
(Date:3/27/2015)... SHANGHAI , March 27, 2015 ... China International Exhibition of Senior Care, Rehabilitation Medicine and ... senior service industry, will be held at Shanghai ... On 25 February, 2015,  Implementation Suggestions on Encouraging ... Service Industry, which was jointly issued by the Ministry ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6
(Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... March 28, 2015 Emergency Medical Care ... care in Manhattan, recently commemorated its three-year anniversary of ... Manhattan. In addition to 24-hour urgent care, Emergency Medical ... , At this time, Emergency Medical Care’s Urgent ... asthma, chest pain, eye injuries, ear infections, fevers, insect ...
(Date:3/28/2015)... Centurion Service Group will be hosting a live on-site ... their Las Vegas warehouse, located at 4606 Andrews St. Suite ... of equipment from hospitals and surgery centers from around the ... , Buyers will find items of all types including anesthesia, ... said Erik Tivin, CEO of Centurion. , Among the sale’s ...
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... lead the global angiography, fluoroscopy and X-ray business , , ... the new CEO of Siemens Healthcare,s U.S. ... position, Reitermann will lead the marketing, sales and service functions for ... medical imaging, therapy and health care information technology businesses. He ...
... the first effective treatment in the fight against malaria ... this devastating disease. But the drug is associated with a ... and headaches to blindness, deafness and in rare cases death ... at The University of Nottingham have made a discovery that ...
... Texas, June 29 The physicians of Hematology-Oncology ... provider community based specialty practice caring for adults with cancers ... agreement with Oncology Pharmaceutical Services (OPS) ... support of an oncology-trained consultant pharmacist. , , By ...
... Couple, Clovis Students Win Thousands of Dollars in Milk Contest ... struggle month after month with Premenstrual Syndrome, a.k.a. man,s worst ... of whom do not yet know that milk could be ... an effort to educate women on the PMS-fighting benefits of ...
... ... on Drug Abuse (VIDA) working in collaboration with colleagues at Vector Tobacco, Inc. and Duke ... better chance at kicking the tobacco habit. , ... Manhasset, NY (Vocus) June 29, 2009 -- Scientists at the ...
... Corporation (Nasdaq: AIRM ), the largest air medical ... a petition with the National Transportation Safety Board (NTSB) requesting ... June 29, 2008 mid-air collision accident in Flagstaff, Arizona. ... to see and avoid the other helicopter on approach to ...
Cached Medicine News:Health News:Michael Reitermann to Head Siemens Healthcare U.S. Organization 2Health News:Breakthrough in combating the side effects of quinine 2Health News:Oncology Group's Pharmaceutical Services Agreement Enhances Efficiency of Drug Management Program 2Health News:Oncology Group's Pharmaceutical Services Agreement Enhances Efficiency of Drug Management Program 3Health News:No More Drama With TOMA LECHE 2Health News:No More Drama With TOMA LECHE 3Health News:No More Drama With TOMA LECHE 4Health News:News from the Latest Issue of Molecular Medicine Kicking The Habit - It's In The Genes 2Health News:Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 2
... solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
... was designed for patients with difficult problems ... custom designs to repair difficult anatomic conditions. ... which reduces the chance of dislocation in ... been streamlined and updated so that the ...
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively....
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
Medicine Products: